Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion

被引:3
作者
Watanabe, Satoshi [1 ]
Inoue, Akira [2 ]
Nukiwa, Toshihiro [3 ]
Kobayashi, Kunihiko [4 ]
机构
[1] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata 9518510, Japan
[2] Tohoku Univ, Dept Med Res, Sendai, Miyagi, Japan
[3] Japan AntiTB Assoc, Chiyoda Ku, Tokyo, Japan
[4] Saitama Int Med Ctr, Resp Med, Hidaka, Saitama, Japan
关键词
Gefitinib; EGFR mutation; non-small cell lung cancer; exon; 19; deletion; L858R; EGFR MUTATIONS; 1ST-LINE TREATMENT; OPEN-LABEL; PHASE-III; AFATINIB; ADENOCARCINOMA; MULTICENTER; ERLOTINIB;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib as first-line treatment has been demonstrated to improve overall survival (OS) in patients with non-small cell lung cancer (NSCLC) harboring an exon 19 deletion (del19) of EGFR compared to platinum-doublet chemotherapy. However, it is unclear whether first-generation EGFR-TKIs improve OS in patients with del19 in the first-line treatment. Patients and Methods: We performed a post-hoc analysis of patients with del19 or L858R mutation of EGFR who received gefitinib in the NEJ002 study, which compared gefitinib to carboplatin-paclitaxel. Results: A total of 58 patients and 57 patients with del19 EGFR received gefitinib and carboplatin-paclitaxel, respectively. No OS differences were observed between patients receiving gefitinib and carboplatin-paclitaxel irrespective of del19 (29.3 months vs. 29.7 months, p= 0.53) or L858R (28.4 months vs. 25.1 months, p= 0.45). Conclusion: In contrast to afatinib, it is suggested that first-line gefitinib does not improve OS in patients with del19 of EGFR compared with platinum-doublet chemotherapy.
引用
收藏
页码:6957 / 6961
页数:5
相关论文
共 50 条
[41]   Management of EGFR mutated non-small cell lung carcinoma patients [J].
Perquis, M. -P. ;
Tissot, C. ;
Bouleftour, W. ;
Bayle-Bleuez, S. ;
Vercherin, P. ;
Forest, F. ;
Fournel, P. .
REVUE DES MALADIES RESPIRATOIRES, 2022, 39 (09) :731-739
[42]   Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer [J].
Batra, Ullas ;
Biswas, Bivas ;
Prabhash, Kumar ;
Krishna, M. Vamshi .
BMJ OPEN RESPIRATORY RESEARCH, 2023, 10 (01)
[43]   Gefitinib in advanced non-small cell lung cancer [J].
Sharma, R ;
Boyer, M ;
Clarke, S ;
Millward, M .
INTERNAL MEDICINE JOURNAL, 2005, 35 (02) :77-82
[44]   Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer [J].
Yosuke Togashi ;
Katsuhiro Masago ;
Satohiro Masuda ;
Tomoyuki Mizuno ;
Masahide Fukudo ;
Yasuaki Ikemi ;
Yuichi Sakamori ;
Hiroki Nagai ;
Young Hak Kim ;
Toshiya Katsura ;
Michiaki Mishima .
Cancer Chemotherapy and Pharmacology, 2012, 70 :399-405
[45]   Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination [J].
Hsiao, Shih-Hsin ;
Chou, Yu-Ting ;
Lin, Sey-En ;
Hsu, Ru-Chun ;
Chung, Chi-Li ;
Kao, Yu-Rung ;
Liu, H. Eugene ;
Wu, Cheng-Wen .
ONCOTARGET, 2017, 8 (32) :53405-53418
[46]   Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer [J].
Chen, Jing ;
Gu, Runxia ;
Wang, Qiong ;
Dassarath, Meera ;
Yin, Zhongyuan ;
Yang, Kunyu ;
Wu, Gang .
ONKOLOGIE, 2012, 35 (09) :509-513
[47]   Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy [J].
Bersanelli, Melissa ;
Buti, Sebastiano ;
Camisa, Roberta ;
Brighenti, Matteo ;
Lazzarelli, Silvia ;
Mazza, Giancarlo ;
Passalacqua, Rodolfo .
CANCERS, 2014, 6 (04) :2035-2048
[48]   Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis [J].
Sheng, Miaomiao ;
Wang, Fang ;
Zhao, Yueguang ;
Li, Shanshan ;
Wang, Xiaojie ;
Shou, Tao ;
Luo, Ying ;
Tang, Wenru .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (01) :1-11
[49]   Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial [J].
Riudavets, Mariona ;
Naigeon, Marie ;
Texier, Matthieu ;
Dorta, Miriam ;
Barlesi, Fabrice ;
Mazieres, Julien ;
Varga, Andrea ;
Cassard, Lydie ;
Boselli, Lisa ;
Grivel, Jonathan ;
NgoCamus, Maud ;
Lacroix, Ludovic ;
Mezquita, Laura ;
Besse, Benjamin ;
Chaput, Nathalie ;
Planchard, David .
LUNG CANCER, 2022, 166 :255-264
[50]   Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer [J].
Yamazaki, Mizuki ;
Komizo, Nao ;
Iihara, Hirotoshi ;
Hirose, Chiemi ;
Yanase, Komei ;
Yamada, Yuto ;
Endo, Junki ;
Yamashita, Shuji ;
Ohno, Yasushi ;
Todoroki, Kenichiro ;
Suzuki, Akio ;
Hayashi, Hideki .
ANTICANCER RESEARCH, 2023, 43 (02) :725-732